Health Condition 1: null- Wuchereia bancrofti infected children
Conditions
Interventions
Intervention1: Albendazole and DEC: Drug doses
5-14 yrs- DEC 200mg + ALB 400 mg orally single dose annually
15-18 yrs- DEC 300 mg + ALB 400mg orally single dose
annually
Control Intervention1: Albenda
Sponsors
Regional Medical Research Centre ICMR Chandrasekharpur Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written consent from parents or guardians 2 Children between 5-18 years age 3. Evidence of filarial diseases like ADL, lymphedema and hydrocele. 4. History of filarial diseases. 5. Evidence of infection i.e. Mf positive or CFA positive or antibody positive for W.bancrofti.
Exclusion criteria
Exclusion criteria: 1. Any systemic disease including cardio vascular or respiratory abnormality. 2. Abnormal liver and kidney function test. 3. Peripheral vascular diseases. 4. History of drug allergy to DEC. 5. H/O taking anti filarials in last one year
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Reversibility of clinical manifestation if found will be a new addition to MDA advocacy tool.Timepoint: Baseline,6,12,18 and 24 months | — |
Primary
| Measure | Time frame |
|---|---|
| 1. Prevalence of subclinical lymphatic pathology in population between 5-18 years with W.bancrofti infection in defined endemic community. 2. Effect of single annual and Biannual dose of DEC plus Albendazole on lymphatic pathology in the identified group. Timepoint: Baseline,6,12,18 and 24 months | — |
Countries
India
Contacts
Public ContactDr B Dwibedi
Regional Medical Research Centre
Outcome results
None listed